Article
BRAF mutation predicts sensitivity to MEK inhibition.
Nature - 19 Jan 2006
Solit David B, Garraway Levi A, Pratilas Christine A, Sawai Ayana, Getz Gad, Basso Andrea, Ye Qing, Lobo Jose M, She Yuhong, Osman Iman, Golub Todd R, Sebolt-Leopold Judith, Sellers William R, Rosen Neal
Abstract excerpt
The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumours, often through gain-of-function mutations of RAS and RAF family members. Using small-molecule inhibitors of MEK and an integrate...
Topics
- Animals
- Benzamides
- Cell Line, Tumor
- Cell Proliferation
- Cyclin D1
- Diphenylamine
- Female
- G1 Phase
- Humans
- Mice
- Mitogen-Activated Protein Kinase Kinases
- Mutation
- Phosphorylation
- Proto-Oncogene Proteins B-raf